MAPK3 and frontotemporal dementia: We tested whether panitumumab affected FTD‐induced phosphorylation of ERK1/2 and AKT and observed that cotreatment of panitumumab with FTD for 24 h suppressed FTD‐induced AKT and ERK phosphorylation (Fig. 3).